Skip to main content

Advertisement

SpringerLink
Log in

Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Redox mechanisms have been shown to be important in malignant cell survival and are a system that may be modified for the treatment of hematologic malignancies. Motexafin gadolinium (MGd) is a synthetic expanded porphyrin that selectively accumulates in tumor cells and oxidizes various intracellular metabolites, including ascorbate, nicotinamide adenine dinucleotide phosphate, glutathione, and protein thiols, to generate reactive oxygen species in a process known as futile redox cycling. The rationale for its use in hematologic malignancies is that, like naturally occurring porphyrins, it tends to concentrate selectively in cancer cells, and it has a novel mechanism of action of inducing redox stress and triggering apoptosis in a broad range of malignancies. MGd induces apoptosis in B-cell non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and highly resistant myeloma cell lines. Furthermore, MGd is additive or synergistic with ionizing radiation, several chemotherapy agents, and rituximab in vitro and in vivo tumor models. Through gene expression profiling, various stress-related genes are upregulated in response to MGd, including genes encoding metallothioneins, heat shock proteins, and heme oxygenase. Preliminary results from clinical trials with MGd in hematopoietic malignancies have shown that it is well tolerated, with minimal hematologic side effects in both; it has single agent activity in very heavily pretreated chronic lymphocytic leukemia /small lymphocytic lymphoma patients, and it has induced prompt complete remissions in combination with 90Yttrium-ibritumomab (Y-90 Zevalin; Biogen Idec Inc., Cambridge, MA) for relapsed non-Hodgkin’s lymphoma in the first two cohorts of patients enrolled. Various clinical trials studying MGd as a single agent and in combination with radiation and/or chemotherapy for the treatment of hematologic malignancies are ongoing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Sessler JL, Miller RA: Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol 2000, 59:733–739.

    Article  PubMed  CAS  Google Scholar 

  2. Magda D, Gerasimchuk N, Lecane P, et al.: Motexafin gadolinium reacts with ascorbate to produce reactive oxygen species. Chem Commun (Camb). 2002:2730–2731.

  3. Xu S, Zakian K, Thaler H, et al.: Effects of Motexafin gadolinium on tumor metabolism and radiation sensitivity. Int J Radiat Oncol Biol Phys 2001, 49:1381–1390.

    Article  PubMed  CAS  Google Scholar 

  4. Magda D, Lepp C, Gerasimchuk N, et al.: Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys 2001, 51:1025–1036. Preclinical study describing redox mechanism of action of motexa-fin gadolinium in combination with radiation in solid tumors.

    Article  PubMed  CAS  Google Scholar 

  5. Evens AM, Lecane P, Magda D, et al.: Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. Blood 2005, 105:1265–1273. Preclinical study documenting significant cytotoxicity of motexafin gadolinium in varied myeloma cell lines through redox and apoptotic-dependent mechanisms.

    Article  PubMed  CAS  Google Scholar 

  6. Rockwell S, Donnelly ET, Liu Y, Tang LQ: Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in vitro. Int J Radiat Oncol Biol Phys 2002, 54:536–541.

    Article  PubMed  CAS  Google Scholar 

  7. Toyokuni S: Reactive oxygen species-induced molecular damage and its application in pathology. Pathol Int 1999, 49:91–102.

    Article  PubMed  CAS  Google Scholar 

  8. Cerutti PA: Prooxidant states and tumor promotion. Science 1985, 227:375–381.

    Article  PubMed  CAS  Google Scholar 

  9. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S: Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999, 94:2102–2111.

    PubMed  CAS  Google Scholar 

  10. Gromer S, Urig S, Becker K: The thioredoxin system-from science to clinic. Med Res Rev 2004, 24:40–89.

    Article  PubMed  CAS  Google Scholar 

  11. Gartenhaus RB, Prachand SN, Paniaqua M, et al.: Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer Res 2002, 8:566–572.

    PubMed  CAS  Google Scholar 

  12. Grad JM, Bahlis NJ, Reis I, et al.: Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001, 98:805–813.

    Article  PubMed  CAS  Google Scholar 

  13. Bellosillo B, Villamor N, Lopez-Guillermo A, et al.: Complement-mediated cell death induced by ritux-imab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001, 98:2771–2777. Study showing a mechanism of rituximab activity in lym-phoproliferative disorders through redox-related mechanisms.

    Article  PubMed  CAS  Google Scholar 

  14. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, et al.: Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002, 8:3658–3668. Clinical trial showing that the activity of arsenic/ascorbic acid therapy in relapsed multiple myeloma is in part dependent on depletion of reducing metabolites (glutathione).

    PubMed  CAS  Google Scholar 

  15. Williamson JM, Boettcher B, Meister A: Intracellular cysteine delivery system that protects against toxicity by promoting glutathione synthesis. Proc Natl Acad Sci U S A 1982, 79:6246–6249.

    Article  PubMed  CAS  Google Scholar 

  16. Meister A: Glutathione metabolism and its selective modification. J Biol Chem 1988, 263:17205–17208.

    PubMed  CAS  Google Scholar 

  17. Sun J, Chen Y, Li M, Ge Z: Role of antioxidant enzymes on ionizing radiation resistance. Free Radic Biol Med 1998, 24:586–593.

    Article  PubMed  CAS  Google Scholar 

  18. Powis G, Montfort WR: Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 2001, 41:261–295.

    Article  PubMed  CAS  Google Scholar 

  19. Dalton WS: Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated deple-tion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002, 8:3658–3668. Clin Cancer Res 2002, 8:3643–3645.

    Google Scholar 

  20. Brookes PS, Levonen AL, Shiva S, Sarti P, Darley-Usmar VM: Mitochondria: regulators of signal transduction by reactive oxygen and nitrogen species. Free Radic Biol Med 2002, 33:755–764.

    Article  PubMed  CAS  Google Scholar 

  21. Byrd JC, Kitada S, Flinn IW, et al.: The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002, 99:1038–1043.

    Article  PubMed  CAS  Google Scholar 

  22. Evens AM, Prachand S, Shi B, et al.: Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent. Clin Cancer Res 2004, 10:1481–1491.

    Article  PubMed  CAS  Google Scholar 

  23. Chen Q, Chai YC, Mazumder S, et al.: The late increase in intracellular free radical oxygen species during apoptosis is associated with cytochrome c release, caspase activation, and mitochondrial dysfunction. Cell Death Differ 2003, 10:323–334.

    Article  PubMed  CAS  Google Scholar 

  24. Li PF, Dietz R, von Harsdorf R: p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apop-tosis blocked by Bcl-2. Embo J 1999, 18:6027–6036.

    Article  PubMed  CAS  Google Scholar 

  25. Woodburn KW: Intracellular localization of the radiation enhancer motexafin gadolinium using interfero-metric Fourier fluorescence microscopy. J Pharmacol Exp Ther 2001, 297:888–894.

    PubMed  CAS  Google Scholar 

  26. Miller RA, Woodburn K, Fan Q, et al.: In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys 1999, 45:981–989.

    Article  PubMed  CAS  Google Scholar 

  27. Young SW, Qing F, Harriman A, et al.: Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci U S A 1996, 93:6610–6615.

    Article  PubMed  CAS  Google Scholar 

  28. Donnelly ET, Liu Y, Fatunmbi YO, et al.: Effects of texaphyrins on the oxygenation of EMT6 mouse mammary tumors. Int J Radiat Oncol Biol Phys 2004, 58:1570–1576.

    Article  PubMed  CAS  Google Scholar 

  29. Miller RA, Woodburn KW, Fan Q, et al.: Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. Clin Cancer Res 2001, 7:3215–3221. Preclinical studies showing synergy of motexafin gadolinium with various chemotherapy agents.

    PubMed  CAS  Google Scholar 

  30. Young SW, Sidhu MK, Qing F, et al.: Preclinical evaluation of gadolinium (III) texaphyrin complex. A new paramagnetic contrast agent for magnetic resonance imaging. Invest Radiol 1994, 29:330–338.

    Article  PubMed  CAS  Google Scholar 

  31. Rosenthal DI, Nurenberg P, Becerra CR, et al.: A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 1999, 5:739–745.

    PubMed  CAS  Google Scholar 

  32. Viala J, Vanel D, Meingan P, et al.: Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. Radiology 1999, 212:755–759.

    PubMed  CAS  Google Scholar 

  33. Carde P, Timmerman R, Mehta MP, et al.: Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 2001, 19:2074–2083. First clinical trial showing activivty of motexafin gadolinium with radiation including tumor-selective uptake.

    PubMed  CAS  Google Scholar 

  34. Mehta MP, Shapiro WR, Glantz MJ, et al.: Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 2002, 20:3445–3453.

    Article  PubMed  CAS  Google Scholar 

  35. Mehta MP, Rodrigus P, Terhaard CH, et al.: Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003, 21:2529–2536. Phase III randomized clinical trial showing combination motexafin gadolinium with brain radiation was superior to radiation alone in varied neurologic endpoints.

    Article  PubMed  CAS  Google Scholar 

  36. Meyers CA, Smith JA, Bezjak A, et al.: Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004, 22:157–165.

    Article  PubMed  CAS  Google Scholar 

  37. Lin TS BS, Naumovski L, Lecane P, et al.: Effects of the Redox Mediator Motexafin Gadolinium in a Pilot Phase I Trial in Refractory Chronic Lymphocytic Leukemia. Presented at the American Society of Hematology (ASH). San Diego, CA; 2004. Early clinical trial studying activity of single-agent motexafin gadolinium in heavily treated chronic lymphocytic leukemia patients.

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 676 N. St. Clair, Suite 850, 60611, Chicago, IL, USA

    Andrew M. Evens DO, MS

Authors
  1. Andrew M. Evens DO, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lakshmi Balasubramanian MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leo I. Gordon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Evens, A.M., Balasubramanian, L. & Gordon, L.I. Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies. Curr. Treat. Options in Oncol. 6, 289–296 (2005). https://doi.org/10.1007/s11864-005-0033-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-005-0033-y

Keywords

Search

Navigation